New imaging trick could spot dangerous prostate cancers earlier
NCT ID NCT07531329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether taking a delayed PET/CT scan 2-3 hours after injection of a radioactive tracer can better detect aggressive prostate cancer compared to the standard 60-minute scan. Researchers will enroll 1,000 men with suspected prostate cancer who have not yet had a biopsy. Each man will act as his own control, and the goal is to see if the delayed scan improves accuracy and could help some men avoid unnecessary biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PSMA PET/CT scan with a radioactive tracer (gallium-68 PSMA-11)
What this could lead to
If successful, this could lead to a more accurate imaging method to detect aggressive prostate cancer, potentially reducing unnecessary biopsies.
What could go wrong
This is a diagnostic study, not a treatment trial. The improvement from delayed imaging may be small, and results may not change clinical practice significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MOLECULAR IMAGING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Yan'an University
RECRUITINGYan’an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, Ningxia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Qinghai University Affiliated Hospital
RECRUITINGXining, Qinghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shaanxi Provincial People's Hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of Lanzhou University
RECRUITINGLanzhou, Gansu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
RECRUITINGXianyang, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Weinan Central Hospita
RECRUITINGWeinan, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xijing 986 Hospital
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xijing Hospital
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact